Skip to main content

Branded

  • Upsher-Smith announces Androxy re-availability

    MAPLE GROVE, Minn. — Upsher-Smith Laboratories on Monday announced that its Androxy (fluoxymesterone) tablets were once again available exclusively through the company. The drug is a synthetic androgen available in 100-count bottles of 10-mg tablets. 
     
    “As the only supplier of fluoxymesterone tablets in the United States, we have made it a priority to get this medication back on the market,” Upsher-Smith president Rusty Field said. “We are pleased that physicians and patients can once again access Androxy.”

  • Allergan acquires Topokine Therapeutics

    DUBLIN and BOSTON — Allergan on Thursday announced that it had acquired topical dermatology company Topokine Therapeutics, which develops medicine for fat reduction.
     
    The acquisition saw Allergan pauying $85 million up front alongside success-based development and milestones for Topokine’s XAF5, an under-eye bag treatment. 
     

  • Tris Pharma launches Dyanavel XR

    MONMOUTH JUNCTION, N.J. — Tris Pharma announced this week that it had launched its Dyanavel XR (amphetamine) extended-release liquid for oral suspension. The drug is indicated to treat attention deficit/hyperactivity disorder (ADHD) in children aged 6 years and older
     

  • Dr. Reddy’s subsidiary announces Zembrace SymTouch U.S. availability

    HYDERABAD, India. — Dr. Reddy’s Laboratories subsidiary Promius Pharma announced Tuesday that its Zembrace SymTouch (sumatriptan injection) is now commercially available in the United Stated. 
     
    The pre-filled, low-dose autoinjector contains 3 mg of sumatriptan, which can lead to rapid migraine relief. 
     

  • Adapt Pharma launches Narcan Now app

    DUBLIN — Adapt Pharma, maker of Narcan (naloxone) Nasal Spray announced Thursday the launch of its smartphone app Narcan Now. The app provides patients information about how to recognize the signs and symptoms of an opioid overdose, an instructional video and  a three-step administration guide for Narcan Nasal Spray, as well as emergency services access. 
     
    The app is available through the iTunes App Store for iOS devices and the Google Play store for Android devices. 
     

  • Biosimilars to save billions

    Zarxio (filgrastim-sndz), the first U.S. biosimilar

    Biologic medications — nine of which were among the Food and Drug Administration’s approvals in 2015 — constitute a big portion of the specialty market, and with the recent introduction of the first U.S. biosimilar, Zarxio (filgrastim-sndz), biologic makers are going to see a shakeup in the coming years as more biosimilars become available.

  • Specialty pharmacy drives prescription growth

    It’s no secret that the category of drugs drawing the most attention — and money — in recent years has been specialty pharmacy. And it shouldn’t be surprising that the growth the category has experienced in the past several years — pushed more recently by hepatitis C and oncology treatments — isn’t expected to slow anytime soon.

  • Congress passes Ensuring Patient Access Act

    ARLINGTON, Va. – The U.S. House of Representatives on Tuesday passed the Ensuring Patient Access and Effective Drug Enforcement Act of 2016 (S. 483) in the same version passed by the Senate, making President Obama’s consideration and signature the final step before enactment.
     
    The legislation, advocated by both retail pharmacy and the pharma industry, would advance collaboration among health and enforcement authorities to achieve drug abuse solutions that maintain patients’ legitimate access to medications.
X
This ad will auto-close in 10 seconds